
Magdalena Niemira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2730666/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Role of Androgen Receptor and microRNA Interactions in Androgen-Dependent Diseases. International Journal of Molecular Sciences, 2022, 23, 1553.	1.8	7
2	Exploring microRNAs as predictive biomarkers for type 2 diabetes mellitus remission after sleeve gastrectomy: A pilot study. Obesity, 2022, 30, 435-446.	1.5	5
3	MicroRNA Profile Alterations in Parathyroid Carcinoma: Latest Updates and Perspectives. Cancers, 2022, 14, 876.	1.7	5
4	miRNAs as Predictive Factors in Early Diagnosis of Gestational Diabetes Mellitus. Frontiers in Endocrinology, 2022, 13, 839344.	1.5	17
5	ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer. Cancers, 2022, 14, 2005.	1.7	1
6	Serum miRNA Profile in Diabetic Patients With Ischemic Heart Disease as a Promising Non-Invasive Biomarker. Frontiers in Endocrinology, 2022, 13, .	1.5	6
7	Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer. Cancers, 2022, 14, 2679.	1.7	7
8	Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	24
9	Reduced expression of innate immunity-related genes in lymph node metastases of luminal breast cancer patients. Scientific Reports, 2021, 11, 5097.	1.6	11
10	Recent Highlights of Research on miRNAs as Early Potential Biomarkers for Cardiovascular Complications of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2021, 22, 3153.	1.8	15
11	Aluminum or Low pH – Which Is the Bigger Enemy of Barley? Transcriptome Analysis of Barley Root Meristem Under Al and Low pH Stress. Frontiers in Genetics, 2021, 12, 675260.	1.1	21
12	Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups. Journal of Pathology: Clinical Research, 2021, 7, 565-576.	1.3	4
13	Gut Microbiome in Chronic Coronary Syndrome Patients. Journal of Clinical Medicine, 2021, 10, 5074.	1.0	13
14	Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression. Journal of Personalized Medicine, 2021, 11, 1088.	1.1	3
15	Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo. Blood, 2021, 138, 2248-2248.	0.6	0
16	Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). Cancers, 2020, 12, 37.	1.7	179
17	Circulating miRNAs as a Predictive Biomarker of the Progression from Prediabetes to Diabetes: Outcomes of a 5-Year Prospective Observational Study. Journal of Clinical Medicine, 2020, 9, 2184.	1.0	29
18	Molecular identification of CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1 and CNS HGNET-BCOR pediatric brain tumors using tumor-specific signature genes. Acta Neuropathologica Communications, 2020, 8, 105.	2.4	33

Magdalena Niemira

#	Article	IF	CITATIONS
19	microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Status—A Pilot Study. Diagnostics, 2020, 10, 617.	1.3	7
20	In search for interplay between stool microRNAs, microbiota and short chain fatty acids in Crohn's disease - a preliminary study. BMC Gastroenterology, 2020, 20, 307.	0.8	12
21	Insulin Resistance and Endometrial Cancer: Emerging Role for microRNA. Cancers, 2020, 12, 2559.	1.7	16
22	Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells. Biomedicines, 2020, 8, 292.	1.4	5
23	Evaluation of Transcriptomic Regulations behind Metabolic Syndrome in Obese and Lean Subjects. International Journal of Molecular Sciences, 2020, 21, 1455.	1.8	12
24	Sex-Specific Glucose Homeostasis and Anthropometric Responses to Sleeve Gastrectomy in Obese Patients. Nutrients, 2019, 11, 2408.	1.7	1
25	Novel Approaches in Ovarian Cancer Research against Heterogeneity, Late Diagnosis, Drug Resistance, and Transcoelomic Metastases. International Journal of Molecular Sciences, 2019, 20, 2649.	1.8	9
26	Prenatal circulating microRNA signatures of foetal Down syndrome. Scientific Reports, 2019, 9, 2394.	1.6	24
27	NF-kappa B Signaling-Related Signatures Are Connected with the Mesenchymal Phenotype of Circulating Tumor Cells in Non-Metastatic Breast Cancer. Cancers, 2019, 11, 1961.	1.7	18
28	The efficacy of family history, genetic risk score and physical activity in distinguishing type 2 diabetes prevalence. Polish Archives of Internal Medicine, 2019, 129, 442-450.	0.3	5
29	Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis. Journal of Neuro-Oncology, 2018, 138, 231-240.	1.4	16
30	The typeÂ2 diabetes susceptibility TCF7L2 gene variants affect postprandial glucose and fat utilization in non-diabetic subjects. Diabetes and Metabolism, 2018, 44, 379-382.	1.4	13
31	MBRS-18. ALK EXPRESSION AT THE PROTEIN LEVEL IS A MARKER FOR THE DIFFERENTIATION DIAGNOSIS OF THE WNT-ACTIVATED TYPE OF PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i132-i132.	0.6	0
32	Maternal plasma metabolic fingerprint indicative for fetal Down syndrome. Prenatal Diagnosis, 2018, 38, 876-882.	1.1	3
33	ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients. American Journal of Surgical Pathology, 2017, 41, 781-787.	2.1	14
34	Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project. Advances in Medical Sciences, 2017, 62, 405-413.	0.9	18
35	The rs340874 PROX1 type 2 diabetes mellitus risk variant is associated with visceral fat accumulation and alterations in postprandial glucose and lipid metabolism. Genes and Nutrition, 2015, 10, 4.	1.2	39
36	Proteomics biomarkers for non-small cell lung cancer. Journal of Pharmaceutical and Biomedical Analysis, 2014, 101, 40-49.	1.4	38

#	Article	IF	CITATIONS
37	CYP3A4â€dependent cellular response does not relate to CYP3A4â€catalysed metabolites of Câ€1748 and Câ€1 acridine antitumor agents in HepG2 cells. Cell Biology International, 2014, 38, 1291-1303.	3Q5 1.4	9
38	Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia. Biochemical Pharmacology, 2013, 86, 231-241.	2.0	21
39	Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells. Biochemical Pharmacology, 2012, 84, 30-42.	2.0	10
40	The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s. Drug Metabolism and Disposition, 2011, 39, 1423-1432.	1.7	22
41	Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells. Xenobiotica, 2011, 41, 1044-1055.	0.5	19